WHICH IS THE MOST ADOPTABLE PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA TREATED WITH R-CHOP FOLLOWED BY AUTOLOGOUS TRANSPLANTATION?
(Abstract release date: 05/21/15)
EHA Library. Lee M. 06/12/15; 102610; PB2027
Disclosure(s): Konkuk University Medical CenterInternal Medicine, Division of Hematology-Oncology
Mark Lee
Contributions
Contributions
Abstract
Abstract: PB2027
Type: Publication Only
Background
The ideal prognostic model has not been developed for patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab combined with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell transplantation (Auto-SCT).
Aims
Among the currently adoptable prognostic models for DLBCL, we investigated to find out which one is the most adoptable one for DLBCL treated with R-CHOP followed by upfront Auto-SCT.
Methods
We retrospectively evaluated survival differences between the risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI) and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront Auto-SCT.
Results
Patients had either stage I/II bulky disease (6.3%) or stage III/IV disease (93.7%). The median age at diagnosis was 50 years (range, 22-66 years). 37 of 63 patients (58.7%) belonged to the IPI high-intermediate or high risk group. 48 of 63 (76.2%) received 6 or more cycles of R-CHOP. The median time to transplantation was 7.2 months (range, 3.4-40.3 months). At the time of Auto-SCT, 74.6% and 25.4% of patients achieved complete (CR) and partial remission (PR) after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to IPI, aaIPI, R-IPI, and NCCN-IPI did not differ in statistical significance between the risk groups of each prognostic model (P values for OS: 0.255, 0.185, 0.881, and 0.803, respectively; P values for PFS: 0.177, 0.832, 0.295, and 0.609, respectively).
Summary
There is no ideal prognostic model among the currently adoptable ones for CD20-positive DLBCL treated with R-CHOP followed by upfront Auto-SCT. A new prognostic model is necessary to identify those who will gain the maximum benefit from upfront Auto-SCT in the rituximab era.
Keyword(s): Autologous hematopoietic stem cell transplantation, Diffuse large B cell lymphoma, Prognostic groups, Rituximab
Session topic: Publication Only
Type: Publication Only
Background
The ideal prognostic model has not been developed for patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab combined with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell transplantation (Auto-SCT).
Aims
Among the currently adoptable prognostic models for DLBCL, we investigated to find out which one is the most adoptable one for DLBCL treated with R-CHOP followed by upfront Auto-SCT.
Methods
We retrospectively evaluated survival differences between the risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI) and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront Auto-SCT.
Results
Patients had either stage I/II bulky disease (6.3%) or stage III/IV disease (93.7%). The median age at diagnosis was 50 years (range, 22-66 years). 37 of 63 patients (58.7%) belonged to the IPI high-intermediate or high risk group. 48 of 63 (76.2%) received 6 or more cycles of R-CHOP. The median time to transplantation was 7.2 months (range, 3.4-40.3 months). At the time of Auto-SCT, 74.6% and 25.4% of patients achieved complete (CR) and partial remission (PR) after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to IPI, aaIPI, R-IPI, and NCCN-IPI did not differ in statistical significance between the risk groups of each prognostic model (P values for OS: 0.255, 0.185, 0.881, and 0.803, respectively; P values for PFS: 0.177, 0.832, 0.295, and 0.609, respectively).
Summary
There is no ideal prognostic model among the currently adoptable ones for CD20-positive DLBCL treated with R-CHOP followed by upfront Auto-SCT. A new prognostic model is necessary to identify those who will gain the maximum benefit from upfront Auto-SCT in the rituximab era.
Keyword(s): Autologous hematopoietic stem cell transplantation, Diffuse large B cell lymphoma, Prognostic groups, Rituximab
Session topic: Publication Only
Abstract: PB2027
Type: Publication Only
Background
The ideal prognostic model has not been developed for patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab combined with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell transplantation (Auto-SCT).
Aims
Among the currently adoptable prognostic models for DLBCL, we investigated to find out which one is the most adoptable one for DLBCL treated with R-CHOP followed by upfront Auto-SCT.
Methods
We retrospectively evaluated survival differences between the risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI) and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront Auto-SCT.
Results
Patients had either stage I/II bulky disease (6.3%) or stage III/IV disease (93.7%). The median age at diagnosis was 50 years (range, 22-66 years). 37 of 63 patients (58.7%) belonged to the IPI high-intermediate or high risk group. 48 of 63 (76.2%) received 6 or more cycles of R-CHOP. The median time to transplantation was 7.2 months (range, 3.4-40.3 months). At the time of Auto-SCT, 74.6% and 25.4% of patients achieved complete (CR) and partial remission (PR) after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to IPI, aaIPI, R-IPI, and NCCN-IPI did not differ in statistical significance between the risk groups of each prognostic model (P values for OS: 0.255, 0.185, 0.881, and 0.803, respectively; P values for PFS: 0.177, 0.832, 0.295, and 0.609, respectively).
Summary
There is no ideal prognostic model among the currently adoptable ones for CD20-positive DLBCL treated with R-CHOP followed by upfront Auto-SCT. A new prognostic model is necessary to identify those who will gain the maximum benefit from upfront Auto-SCT in the rituximab era.
Keyword(s): Autologous hematopoietic stem cell transplantation, Diffuse large B cell lymphoma, Prognostic groups, Rituximab
Session topic: Publication Only
Type: Publication Only
Background
The ideal prognostic model has not been developed for patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab combined with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell transplantation (Auto-SCT).
Aims
Among the currently adoptable prognostic models for DLBCL, we investigated to find out which one is the most adoptable one for DLBCL treated with R-CHOP followed by upfront Auto-SCT.
Methods
We retrospectively evaluated survival differences between the risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI) and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront Auto-SCT.
Results
Patients had either stage I/II bulky disease (6.3%) or stage III/IV disease (93.7%). The median age at diagnosis was 50 years (range, 22-66 years). 37 of 63 patients (58.7%) belonged to the IPI high-intermediate or high risk group. 48 of 63 (76.2%) received 6 or more cycles of R-CHOP. The median time to transplantation was 7.2 months (range, 3.4-40.3 months). At the time of Auto-SCT, 74.6% and 25.4% of patients achieved complete (CR) and partial remission (PR) after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to IPI, aaIPI, R-IPI, and NCCN-IPI did not differ in statistical significance between the risk groups of each prognostic model (P values for OS: 0.255, 0.185, 0.881, and 0.803, respectively; P values for PFS: 0.177, 0.832, 0.295, and 0.609, respectively).
Summary
There is no ideal prognostic model among the currently adoptable ones for CD20-positive DLBCL treated with R-CHOP followed by upfront Auto-SCT. A new prognostic model is necessary to identify those who will gain the maximum benefit from upfront Auto-SCT in the rituximab era.
Keyword(s): Autologous hematopoietic stem cell transplantation, Diffuse large B cell lymphoma, Prognostic groups, Rituximab
Session topic: Publication Only
{{ help_message }}
{{filter}}